David Amsellem
Stock Analyst at Piper Sandler
(4.60)
# 214
Out of 4,876 analysts
146
Total ratings
60%
Success rate
18.97%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Downgrades: Neutral | $9 → $8.5 | $9.28 | -8.36% | 2 | Jun 17, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $115 | $127.19 | -9.58% | 1 | Jun 12, 2025 | |
| AMGN Amgen | Maintains: Overweight | $329 → $328 | $280.32 | +17.01% | 3 | May 16, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $9.97 | +80.54% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $30.07 | +23.07% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $108.53 | +35.45% | 14 | May 7, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 → $154 | $126.83 | +21.42% | 10 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $46.73 | +39.10% | 1 | Apr 22, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $128 → $131 | $74.68 | +75.42% | 7 | Apr 3, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $23.24 | +37.69% | 8 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $4.67 | -14.26% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $13.63 | -4.62% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $9.10 | +9.95% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $16.86 | +77.94% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $9.20 | +41.30% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $8.17 | +34.72% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $28.88 | +28.14% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $64.90 | +4.78% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $31.29 | +15.05% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.65 | -54.85% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $23.60 | +78.00% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.27 | +205.81% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.74 | +2,727.14% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $106.01 | +6.59% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $31.89 | +31.70% | 3 | Oct 16, 2023 |
Sage Therapeutics
Jun 17, 2025
Downgrades: Neutral
Price Target: $9 → $8.5
Current: $9.28
Upside: -8.36%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $115
Current: $127.19
Upside: -9.58%
Amgen
May 16, 2025
Maintains: Overweight
Price Target: $329 → $328
Current: $280.32
Upside: +17.01%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $9.97
Upside: +80.54%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $30.07
Upside: +23.07%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $108.53
Upside: +35.45%
Neurocrine Biosciences
May 6, 2025
Reiterates: Overweight
Price Target: $160 → $154
Current: $126.83
Upside: +21.42%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.73
Upside: +39.10%
Corcept Therapeutics
Apr 3, 2025
Maintains: Overweight
Price Target: $128 → $131
Current: $74.68
Upside: +75.42%
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $23.24
Upside: +37.69%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $4.67
Upside: -14.26%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $13.63
Upside: -4.62%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $9.10
Upside: +9.95%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.86
Upside: +77.94%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $9.20
Upside: +41.30%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $8.17
Upside: +34.72%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $28.88
Upside: +28.14%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $64.90
Upside: +4.78%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $31.29
Upside: +15.05%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.65
Upside: -54.85%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $23.60
Upside: +78.00%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.27
Upside: +205.81%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.74
Upside: +2,727.14%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $106.01
Upside: +6.59%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $31.89
Upside: +31.70%